

Appendix Tables

Table S1. International Classification of Disease (ICD-9-CM) codes used to identify diabetes, hypertension, and CKD

Comorbidity	ICD-9-CM Codes
Diabetes	250
Chronic Kidney Disease	403, 404, 580, 581, 582, 583, 585, 586, 587, 588, 591, 593, 753, V56
Hypertension	401, 402, 403, 404, 405, 642, 362.11, 416.0, 437.2, 796.2

Table S2. Anatomical therapeutic chemical (ATC) codes used to classify medications

Medication Type	ATC Codes
Antihypertensives (antiadrenergic agents, diuretics, beta blocking agents, and calcium channel blockers)	C02, C03, C07, C08
Angiotensin-Converting Enzyme-Inhibitors (ACEIs)/ Angiotensin Receptor II Blockers (ARBs)	C09
Antihyperglycemic	A10

Table S3. Characteristics of the FINISHED intervention group and the comparison group (post-matching) from available administrative data.

	Intervention Group (n= 324)	Comparison Group (n= 648)	Standardized Difference
Age at screening	12.7 ± 3.1	12.6 ± 2.0	0.03
Sex (% female)	56.2%	55.6%	0.01
Dwelling Location (% Rural)	41.0%	40.9%	-0.003
Chronic Pulmonary Disease	7.10%	6.48%	0.02
Diabetes	3.5%	1.5%	0.06
Renal Disease	<i>suppressed</i>	<i>suppressed</i>	0

Notes. The presence of comorbidities was assessed based on International Classification of Diseases codes taken from hospital admissions and medical claims data from within the 18 months prior to the index date (date of screening, or the pseudo-index date for the control group).

Table S4: Rates of follow-up outpatient testing, and primary care visits by residence (n=324)

	Rural Dwellers (n=133)				Remote Dwellers (n=191)				Difference in % change between the rural vs the remote groups ^b
	% in the 18 months prior to screening	% in the 18 months following screening	% Difference (95% CI) ^a	% with testing/care following screening, to end of databases	% in the 18 months prior to screening	% in the 18 months following screening	% Difference (95% CI) ^a	% with testing/care following screening, to end of databases	
eGFR testing, <i>n</i> (%)	<i>Suppressed</i>	<i>Suppressed</i>	11.3 (4.4, 18.2)	53 (40.0)	<i>Suppressed</i>	<i>Suppressed</i>	8.9 (0.8, 17.1)	87 (45.5)	-2.4 (-13.7, 9.0)
UACR/UPCR testing, <i>n</i> (%)	<i>Suppressed</i>	<i>Suppressed</i>	6.0 (1.1, 11.0)	17 (12.8)	<i>Suppressed</i>	<i>Suppressed</i>	6.3 (0.8, 11.8)	31 (16.2)	0.3 (-7.5, 8.1)
HbA1c, <i>n</i> (%)	<i>Suppressed</i>	<i>Suppressed</i>	3.0 (-2.0, 8.0)	25 (18.8)	<i>Suppressed</i>	<i>Suppressed</i>	7.3 (0.6, 14.1)	51 (26.7)	4.3 (-4.7, 13.4)
At least 1 Primary Care Visit, <i>n</i> (%)	95 (71.4)	107 (80.4)	9.0 (-1.2, 19.2)	124 (93.2)	76 (39.6)	86 (44.8)	4.7 (-5.2, 14.6)	133 (69.6)	-4.3 (-18.9, 10.3)

^a The % difference was calculated as follows: (the % frequency in the post-intervention period – the % frequency in the pre-intervention period).

^b The difference in % change was calculated as follows: [(% frequency following screening in the *remote dwellers* - % frequency preceding screening in the *remote dwellers*) – (% frequency following screening in the *rural dwellers* - % frequency preceding screening in the *rural dwellers*)